The Psoriasis Pipeline: Upcoming New Systemic Drugs | Andrew Blauvelt, MD, MBA | United States

Innovations in Systemic Treatments for Psoriasis | Andrew Blauvelt, MD, MBA | United StatesПодробнее

Treatment of Psoriatic DiseaseПодробнее

Watch Drs. Armstrong & Blauvelt discuss the latest #Psoriasis updates: bit.ly/ElevateDerm24YПодробнее

A KOL Perspective- Exclusive Interview with Dr. Andrew Blauvelt Part 1Подробнее

Hot Psoriasis Topics: Single Cell RNA Sequencing | Andrew Blauvelt, MD, MBA | United StatesПодробнее

Considering Comorbidities in Treatment Planning | Andrew Blauvelt, MD, MBA | United StatesПодробнее

A KOL Perspective- Exclusive Interview with Dr. Andrew Blauvelt Part IVПодробнее

How to KNOCK OUT Disease Memory | Andy Blauvelt, MD, MBA | United StatesПодробнее

Ixekizumab vs. guselkumab in plaque psoriasis, A. Blauvelt et alПодробнее

Ixekizumab vs. guselkumab in plaque psoriasis, Blauvelt et alПодробнее

Management of psoriasis with biologics during the COVID-19 pandemic | Paolo Gisondi, MD | ItalyПодробнее

Ch 2: Defining the new consensus on categorizing patients with psoriasisПодробнее

Trailer: In Conversation: A New Method of Classifying Psoriasis Severity from IPCПодробнее

Current and Novel Treatments | Filip Rob, MD, PhD | Czech RepublicПодробнее

The TYK2 Pathway as a Novel Nonbiologic Oral Therapeutic Option in Moderate to Severe PsoriasisПодробнее

Ch 3: Communicating the strengths, limitations, and barriers to adoption of new consensus guidelinesПодробнее

Does Systemic Therapy for Psoriasis Improves Heart Disease in Clinical Trials? | Joel Gelfand, MDПодробнее